Haihua Yu
余海华
Haihua Yu (余海华) is the co-founder and CEO of Bivision Pharmaceuticals (晶核生物), a biotech company focused on visualized theranostic targeted radionuclide therapy (TRT) for cancer treatment. Per Gaorong Ventures' reporting, he founded the company in 2021 together with three other experienced drug R&D scientists, including Dr. Yu Wang , and has spoken publicly as its CEO around its Series A financing to advance global clinical development . Elsewhere's corpus covers him only through these company-related pieces — no further biographical detail is available.
AI-generated — may contain errors, please verify.
Coverage
Jinghe Biotech Closes Nearly RMB 400 Million Series B Round, Continues to Lead Domestic Targeted Radiopharmaceutical Innovation
Patient-centered, relentlessly refined.
Interview with RayzeBio: Two Funding Rounds in Six Months, How the Surging "Radiopharma" Sector Is Transforming Cancer Treatment | Gaorong Ventures
Accelerating on the "fast track" of TRT therapy.
CoreVision Biopharma Closes Series A to Accelerate Global Clinical Development of Targeted Radiopharmaceuticals
Advancing a BIC/FIC dual-driven pipeline with a global perspective.
CoreVision Biopharma Closes Nearly RMB 100 Million Angel Round, Pioneering Visualized Theranostic Targeted Radiopharmaceuticals
Dedicated to becoming a trailblazer in China's TRT space.
